STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 31 July 2004 please refer to module 8B.  
• 
• 
• 
The MAH submitted on 22 April 1999, an application for a Notification of a Type I Variation 
No  1  of  Annex  I,  in  order  to  apply  for  a  change  in  the  name  of  the  manufacturer  of  the 
medicinal  product,  pursuant  to  Article  4  of  Commission  Regulation  (EC)  No  542/95  of  10 
March 1995, as amended. The procedure started on 29 April 1999. A positive Notification was 
signed  by  the  Head  of  Human  Unit  at  the  EMEA  on  25  May  1999  and  forwarded  to  the 
European Commission, which adopted a decision on 29 July 1999. (EMEA/H/C/206/I/01)  
The MAH submitted on 22 April 1999, an application for a Notification of a Type I Variation 
No 11 of Annex I, in order to apply for a change in the name of the manufacturer of the active 
substance, pursuant to Article 4 of Commission Regulation (EC) No 542/95 of 10 March 1995, 
as amended. The procedure started on 29 April 1999. A positive Notification was signed by the 
Head  of  Human  Unit  at  the  EMEA  on  25  May  1999  and  forwarded  to  the  European 
Commission, which adopted a decision on 29 July 1999. (EMEA/H/C/206/I/02)  
The  MAH  submitted  on  22  April  1999  a  Notification  to  the  EMEA  in  order  to  introduce 
changes  to  the  Package  Leaflet  not  connected  to  the  Summary  of  Product  Characteristics, 
pursuant to Article 10(3) of Council Directive No. 92/27/EEC of 31 March 1992. The procedure 
started  on  29  April  1999.  The  Notification  was  signed  by  the  Head  of  Human  Medicines 
Evaluation Unit on 25 May 1999 and forwarded to the European Commission, which adopted a 
decision on 29 July 1999 (EMEA/H/C/206/N/03). 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Minor change in the manufacturing process of the active ingredient 
Update of Summary of Product Literature and leaflet 
Change(s) to the test method(s) and/or specifications for the active 
substance & Change(s) to the test method(s) and/or specifications 
for the finished product 
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 61.3 Notification) 
Update of Summary of Product Characteristics and Package Leaflet 
Update of or change(s) to the pharmaceutical documentation 
Renewal 
I/04 
II/05 
II/06 
N/07 
II/08 
II/09 
R/10 
I/II 
II 
II 
N 
II 
II 
R 
Notification/ 
Opinion 
issued on2 
16.11.00 
23.08.01 
23.01.03 
Commission 
Decision 
Issued/amen
ded on 
28.01.02 
28.01.03 
15.11.02 
16.12.02 
25.09.03 
17.12.03 
26.02.04 
27.01.04 
23.12.03 
17.06.04 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
 
